Die nachfolgenden Ergebnisse sind möglicherweise die "Reproduktionsversuche" der Untersuchung mit Hypericin (nicht Hypericin-Extrakt !) beim Glioblastom von 1998. An der damaligen Phase I/II Studie nahm auch ein deutscher GBM-Patient teil, der zuvor (aufgrund eines Rezidivs und der fehlenden Therapieoptionen) von seinem Neurochirurgen zum Sterben nach Hause geschickt wurde. In den folgenden Verlaufskontrollen war auf seinen MR-Bildern nur noch wenig KM-Anreicherung in Bezug auf den Tumor zu sehen. Der Patient hatte keine zusätzliche Medikation. Dieser Zustand blieb über viele Monate stabil. Es war ein Schlüsselerlebnis für den behandelnden Neurochirurgen, wie er in einem Vortrag auf dem Informationstag der Hirntumorhilfe berichtete.
Cancer. 2011 Nov 1;117(21):4905-15. doi: 10.1002/cncr.26123. Epub 2011 Mar 31.
A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas.
Couldwell WT1, Surnock AA, Tobia AJ, Cabana BE, Stillerman CB, Forsyth PA, Appley AJ, Spence AM, Hinton DR, Chen TC.
BACKGROUND:
Hypericin ( XH157 )is a potent inhibitor of glioma growth in vitro. To examine whether synthetic oral hypericin can be tolerated by patients with recurrent malignant gliomas (anaplastic astrocytoma and glioblastoma) and to investigate its efficacy against these tumors, the authors undertook an open-label, sequential dose escalation/de-escalation tolerance study.
METHODS:
Patients with documented recurrent or progressive malignant gliomas who had received standard radiation therapy with or without chemotherapy were included. Patients were excluded for previous treatment with agents known to contain hypericin or treatment within 30 days with medications known to cause photosensitivity. Enrolled patients were given gradually increasing dosages of oral synthetic hypericin (0.05-0.50 mg/kg) for up to 3 months if no toxicity was observed, and patient response to treatment was noted. The patients were examined each month and underwent magnetic resonance imaging to evaluate tumor status at 3 months.
RESULTS:
Synthetic hypericin administered orally appeared to provide stabilization or a slight (<50%) decrease in tumor volume (coded as stable disease) at 3 months for 7 of 42 patients (17%) and produced a tumor reduction >50% (partial response) in 2 patients (5%). Seventeen patients (40%) survived for 3 months on daily synthetic hypericin at dose levels of 0.33 ± 0.070 mg/kg daily. The mean maximum tolerated dose was 0.40 ± 0.098 mg/kg daily. Twelve patients continued on hypericin therapy beyond 3 months. The median survival was 26 weeks (Kaplan-Meier method).
CONCLUSIONS:
The results of this study indicated that synthetic, oral hypericin is well tolerated in this patient group. The response results were comparable to those reported from other studies of salvage therapies for recurrent malignant brain tumors.
Copyright © 2011 American Cancer Society.